Hemoglobin released into the circulation during hemolysis or therapy with chemically modified hemoglobins, exert oxidative and NO-scavenging toxic effects. Pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) is one of the second-generation hemoglobinbased oxygen carriers (HBOCs). We wanted to investigate the metabolism of PHP with a special focus on its consequences for interpreting hemolysis-related diagnostic parameters in PHP-treated patients. Clinical samples were analyzed from 3 patients, who received PHP (as part of the PHOENIX phase III trial) for treatment of catecholamine-resistant distributive shock. In contrast to expectations, clearance of PHP by hemopexin, instead of haptoglobin was documented by increased hemolysis indices, absence of decreased haptoglobin values, presence of free PHP-hemoglobin and exhausted hemopexin concentrations.
INTRODUCTION
Hemoglobin-based oxygen carriers (HBOCs) have been the subject of a number of clinical trials for many years as artificial oxygen carriers. Hemoglobin-based therapeutics are produced by modification of ultrapurified or stroma-free hemoglobin, using a variety of intermolecular or intramolecular reactions as cross-linking, conjugation or polymerization. Pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) is one of the second-generation HBOCs (1, 2, 3) . It is a humanderived, chemically modified hemoglobin designed for treatment of shock associated with systemic inflammatory response syndrome (SIRS), a nitric oxide (NO) induced shock. Key symptoms of septic shock are severe hypotension and vasoplegia, ultimately resulting in dysfunction of one or more vital organs, which contributes to significant morbidity and mortality. Since NO, an endothelium-derived relaxing factor, plays an important role in the physiological and pathological control of the vascular tone, NO-scavengers are of interest as therapeutics who might prevent toxicitiy and/or shock caused by excessive NO (4) . PHP was designed to reduce free radicalmediated oxidative stress and scavenge excess NO in catecholamine-resistant septic shock (2, 3) . PHP is conjugated with polyoxyethylene, which results in a surface-decorated molecule with enhanced circulation time and stability. It is also polymerized with catalase and superoxide dismutase to was normal during treatment (reference values: 0.3-2.0 g/L). In contrast, serum hemopexin was virtually absent (reference values: 0.4-1.5 g/L). Serum alpha 1 microglobulin concentration was measured for one patient (case 3) and showed variable results that however did never fall below the reference values (30-80 mg/L). Total bilirubin values were within the reference range (0.2-1.1 mg/dL) for case 3, while for case 2 values tended to increase during the admission on the intensive care unit because of multi-organ failure (Table 1) . Table 1 summarizes the evolution of the major hemolysisrelated parameters in two PHP treated patients (case 2 and 3). The increase of the serum hemolysis index and complexed haptoglobin, and the depletion of hemopexin lasted more than 6 to 9 days, slowly returning to normal values. The observed trends were consistent with the duration of PHP treatment, as they received the product for 6 and 4 days, respectively.
Hemoglobin scavenging analysis
Starch gel electrophoresis followed by peroxidase staining was performed for only one patient (case 3) and demonstrated the presence of free hemoglobin in various serum samples of the patient taken during PHP treatment, an excess of modified hemoglobin (PHP-hemoglobin) was suspected. Since PHP is a chemically modified hemoglobin, a somewhat different migration pattern compared with normal hemoglobin, could be suspected. PHP is characterized by a peak average molecular mass (size exclusion chromatography) of about 106 kDa (1) . The molecular modification is due to the incorporation of an apolar moiety (polyoxyethylene), so that charge of the molecule is only slightly affected. Since the PHP molecular mass (106 kDa) is higher than that of natural hemoglobin (64 kDa), one can notice (as expected) a somewhat slower migration of PHP compared with Hb ( Figure 2) . A decline in free PHP-hemoglobin was observed from day 5 till day 14 during PHP treatment, which correlated well with the decline in hemolysis index. The serum samples taken on day 9 till day 14 showed a hemolysis index that returned to normal, which correlated with the nearly complete absence protect itself to oxidative modification and subsequent ferrylhemoglobin formation (1) . These antioxidant properties, in addition to the NO-scavenging properties, may allow the use of PHP in other indications in which excess NO, superoxide, or hydrogen peroxide is involved, including ischemia-reperfusion injury and hemorrhagic shock (1, 2, 3) .
Little is known about the handling of PHP by the human plasma proteins and the consequences for interpretation of hemolysis-related parameters. In human extracellular fluids, free hemoglobin, released during hemolysis, is recognized and bound by haptoglobin. Haptoglobin-hemoglobin complexes are cleared by the specific CD163 macrophage receptor. When haptoglobin has been exhausted, heme derivates are complexed by hemopexin and subsequently these hemopexin complexes are cleared by the CD91 pathway. Haptoglobin and hemopexin levels are diagnostically used in clinical laboratory medicine as hemolysis markers. In the present study, we wanted to investigate the metabolism of PHP (a pharmaceutically modified hemoglobin) with a special focus on its consequences for interpreting hemolysis-related diagnostic parameters in PHP-treated patients.
MATERIALS AND METHODS

Patients
Clinical samples were analyzed from 3 patients admitted to the intensive care unit of the University Hospital of Ghent in 2011. They all received PHP (Curacyte AG) by continuous intravenous infusion at 0.25 mL/kg/hr for a maximum of 150 hours (as part of the PHOENIX phase III trial) for the treatment of catecholamine-resistant distributive shock. The publication of the results was approved by Curacyte AG.
Methods
Routine biochemical markers were assayed on a Cobas 6000 analyser (Roche, Mannheim, Germany). The hemolysis index was assayed by photometry at 415 nm on a Cobas 6000 analyser (5) . Hemoglobin was determined on a Sysmex XE-5000 analyser (Sysmex, Kobe, Japan). Visible absorbance spectroscopy of the serum was carried out on a Beckman DU-70 photometer. Serum hemopexin, alpha 1 microglobulin and haptoglobin were assayed using immunonephelometry on a BN II nephelometer (Siemens, Marburg, Germany) (6, 7, 8) . Analysis of circulating haptoglobin complexes, haptoglobin phenotype and haptoglobin saturation was carried out using starch gel electrophoresis of the serum followed by peroxidase staining (7).
RESULTS
Hemolysis testing
During admission on the intensive care unit and during PHP treatment, we received several samples showing a hemolytic aspect for the 3 cases. They all yielded very high hemolysis indices with normal to decreased hemoglobin concentrations (reference values: 11.7-15.7 g/dL) ( Figure 1) .
As in the diagnostic work-up of suspected hemolysis, haptoglobin and hemopexin were measured for two patients (case 2 and 3) . Surprisingly, serum haptoglobin concentration * PHP therapy was initiated 18 hours after blood sampling on day 1. ** PHP therapy was administered for 4 days and blood sampling on day 6 was done 7 hours before therapy was discontinued. * PHP therapy was initiated 17 hours after blood sampling on day 1. ** PHP therapy was administered for 6 days and blood sampling on day 8 was done 20 minutes after therapy was discontinued.
Recently an unusual condition due to a temporary inhibition of the CD163 hemoglobin scavenger pathway has been described during an acute HIV-1 retroviral syndrome (13) . Impaired hemoglobin scavenging has also been described in patients treated with gemtuzumab ozogamicin (Mylotarg), a CD33-targeted drug (10) . A significant part of the CD163 positive monocytes and macrophages were eradicated during therapy, because these cells of the liver, spleen and bone marrow coexpress CD33 (10) . Both publications underline the importance of awareness of impaired hemoglobin scavenging as a cause of an unexplained acute inflammatory syndrome.
When using starch gel electrophoresis, we could not detect hemoglobin-haptoglobin complexes; instead we observed high quantities of free hemoglobin (PHP hemoglobin). We believe that the exhaustion of the hemopexin concentrations was probably the consequence of failure of clearing PHP hemoglobin by haptoglobin. The interactions between both are influenced by the physical and chemical properties of Hb. Previous studies have shown that deviations in a-and b-globin chains can interfere in the binding between haptoglobin and hemoglobin. Hb a-subunit accessibility seems critical for haptoglobin binding, as Hbs possessing b-gobin cross-linking, irrespective of polymerization, demonstrate increased haptoglobin affinity compared with a-globinstabilized Hbs (14) . The data show that PHP is cleared by hemopexin and not by the CD163 pathway (Figure 3) .
Combined high hemolysis indices and elevated haptoglobin concentrations are also seen in blood samples undergoing in vitro hemolysis, however this was excluded by careful sampling, findings of normal potassium levels and consecutive serum samples showing a hemolytic aspect. Of note, serum hemopexin concentrations were found to be depleted in fulminant rhabdomyolysis in presence of elevated serum myoglobin concentrations with normal haptoglobin and hemoglobin concentrations (11) . A combination of additional biochemical of free PHP-hemoglobin in these samples. In vitro supplementation of hemoglobin to the patient's serum taken on day 12 and 14 revealed the presence of complexes of Hp 2-1 phenotype (Hb-Hp complexes) and free hemoglobin, associated with a normal binding capacity of the circulating haptoglobin.
DISCUSSION
Patients treated with chemically modified Hbs can present with diagnostic difficulties in interpreting hemolysisrelated parameters. We evaluated the biochemical pattern and abnormalities in two PHP-treated patients.
The macrophage specific CD163 hemoglobin: haptoglobin scavenging pathway plays a major role in removing hemoglobin following hemolysis. Under physiological conditions, haptoglobin: hemoglobin complexes are instantly cleared from plasma with a half-life time of < 10 min (7, 9, 11) . Since hemopexin and alpha 1 microglobulin have a much lower affinity for heme than the affinity of haptoglobin towards hemoglobin, serum hemopexin and alpha 1 microglobulin values only tend to decrease when circulating haptoglobin has been depleted (8, 11, 12) .
The hemolytic aspect of the serum, the increased haptoglobin values (partly acute phase driven) and the apparently exhausted CD91-mediated hemopexin-heme scavenging pathway represents a paradox with the generally accepted physiological mechanisms described above in removing hemoglobin following hemolysis. Following termination of PHP therapy, a restoration of the major hemoglobin scavenging pathway occurred and the hemopexin concentrations slowly recovered (Table 1) . So, an impairment or temporary inhibition of the CD163 hemoglobin scavenger pathway could be suspected; resulting in either an accumulation of free hemoglobin (PHP hemoglobin) or in an accumulation of circulating hemoglobin-haptoglobin complexes. parameters, like CK activity, can be used to diagnose such a condition. The present case report is important for both clinicians and laboratorians since it nicely illustrates that a hemolytic aspect of plasma is not necessarily synonymous for hemolysis ( Table 2) . A hemolytic aspect of plasma or serum (high hemolysis index) in combination with normal (0.3 -2.0 g/L) or increased haptoglobin values should draw the attention; additional determination of lactate dehydrogenase and hemopexin (11, 13) may then be useful to distinguish the condition from in vitro hemolysis and to monitor the in vivo elimination of the heme compounds.
